New Delhi: As per market research and competitive intelligence provider, Fact.MR, the global COVID-19 saliva-based detection kits market was valued at US$ 1.4 Bn in 2020, with demand expected to decline at a CAGR of -2.8% over the forecast period (2021-2031).
COVID-19 is a severe and infectious disease, with diagnosis at the initial stage playing a significant role in stopping the further increase of cases. At present, the old method of sampling, i.e., nasopharyngeal swab is majorly used for testing. However, the emerging technique of saliva-based testing is a promising alternative for COVID-19 diagnosis.
When patients need to get urgent care for more critical flu-like symptoms, physicians need to perform diagnostic tests as soon as possible. To meet this requirement, test kits should be available at cheaper costs, easy to handle, rapid, and equipment-free. This creates an opportunity for market players to come up with innovative devices to fulfil the requirements of patients and physicians in the future.
Due to rising approvals of COVID-19 test kits that are convenient and simple to use, manufacturers are aiming to introduce new products in the market and get them approved.
-
For Instance, in July 2021, Nalagenetics and Nusantics obtained regulatory approval to launch PCR test kits to detect COVID-19 from saliva samples. These kits will function as alternatives to nasal and throat swab tests.
Leading players are focusing on advancements in in-vitro diagnostic procedures with rapid testing. These advancements are expected to gain popularity and generate high revenue in the market.
-
For instance, in April 2021, Therma Bright Inc. announced that it had received CE approval from an EU-competent authority of Belgium for its AcuVid™ COVID-19 rapid antigen saliva test.
Key Takeaways from Market Study
-
By product, PCR-based kits hold around 73.5% value share of the global market in 2021.
-
Based on technology, RT-qPCR is leading with 49.2% market share in 2021.
-
Based on application, COVID-19 diagnosis is leading with 63.1% market share in 2021.
-
By end user, diagnostic laboratories dominate the market with a value share of 26.8% in 2021, while on the other hand, academic and research institutes are expected to increase at a higher CAGR of 2.5%.
-
By country, the U.S. dominates the North America market with a value share of 91% in 2021.
“Rising awareness of home-based testing of SARS COV-2 infection and adoption of saliva-based detection as a feasible specimen are expected to drive market growth over the decade,” says a report analyst.
Who is Winning?
The global market is set to expand due to rise in awareness of early detection of COVID-19 infection. Leading industry players are set to focus on research & development so that they can come up with unique products to strengthen their product portfolios.
-
In Aug 2020, Lenexa received FDA approval for a saliva-based COVID-19 test.
-
In April 2021, Qiagen launched artus Prep as a CE-Marked SARS-CoV-2 test.
